Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

3.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.9K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

631
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
631
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

391
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
391
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

479
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
479
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

4.4K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.4K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

440
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
440

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Functional and Metabolic Adaptations of Blood Flow Restriction Exercise in Rats and Post-surgical Patients.

medRxiv : the preprint server for health sciencesĀ·2026
Same author

Precancer exercise capacity and metabolism during tumor development coordinate the skeletal muscle-tumor metabolic competition.

Proceedings of the National Academy of Sciences of the United States of AmericaĀ·2025
Same author

Interactions among tumor subtype, PPARĪ³ expression, and adipose proliferation shape outcomes in breast cancer.

Physiological reportsĀ·2025
Same author

Germline Variants Influence Chronic Liver Disease Progression through Distinct Pathways.

medRxiv : the preprint server for health sciencesĀ·2025
Same author

Supplementation with GPR120 (Ffar4) ligand omega-3 does not improve survival in murine sepsis models.

American journal of physiology. Endocrinology and metabolismĀ·2025
Same author

Interactions Among Tumor Subtype, PPARĪ³ Expression, and Adipose Proliferation Shape Outcomes in Breast Cancer.

medRxiv : the preprint server for health sciencesĀ·2025

Related Experiment Video

Updated: Nov 28, 2025

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

10.9K

Imeglimin: Current Development and Future Potential in Type 2 Diabetes.

Chigoziri Konkwo1,2, Rachel J Perry3,4

  • 1Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.

Drugs
|November 28, 2020
PubMed
Summary

Imeglimin, a novel drug for type 2 diabetes mellitus (T2DM), enhances mitochondrial function and insulin secretion. Clinical studies show efficacy comparable to existing treatments with a favorable safety profile, offering a promising new therapeutic option.

More Related Videos

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets
10:09

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Published on: May 11, 2015

9.8K
Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

70.6K

Related Experiment Videos

Last Updated: Nov 28, 2025

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

10.9K
Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets
10:09

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Published on: May 11, 2015

9.8K
Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT

Published on: January 7, 2018

70.6K

Area of Science:

  • Pharmacology
  • Endocrinology
  • Mitochondrial Biology

Background:

  • Type 2 diabetes mellitus (T2DM) remains a significant global health challenge.
  • Existing T2DM treatments have limitations and varying safety profiles.
  • There is a need for novel therapeutic agents with distinct mechanisms of action.

Purpose of the Study:

  • To review the mechanism of action of imeglimin, a novel class of T2DM drug.
  • To contextualize imeglimin within the current landscape of T2DM treatment.
  • To summarize preclinical and clinical findings on imeglimin's efficacy and safety.

Main Methods:

  • Review of preclinical rodent models detailing mitochondrial bioenergetics and metabolic effects.
  • In vitro and in vivo studies assessing glucose uptake, production, and insulin secretion.
  • Analysis of human clinical trial data on imeglimin's efficacy, safety, and combination therapy.

Main Results:

  • Imeglimin improves mitochondrial complex II and III metabolism, enhancing fatty acid oxidation and reducing hepatic lipid accumulation.
  • It increases muscle glucose uptake, decreases hepatic glucose production, and enhances insulin secretion.
  • Clinical trials demonstrate efficacy comparable to metformin and sitagliptin, with a benign safety profile, particularly in patients with chronic kidney disease.

Conclusions:

  • Imeglimin represents a novel therapeutic approach for T2DM, targeting mitochondrial function and insulin secretion.
  • Its unique mechanism and favorable safety profile suggest potential for broad patient applicability.
  • Imeglimin shows promise as a standalone or combination therapy for managing type 2 diabetes mellitus.